Loading data for TLX — first visit, this takes a few seconds.
Telix Pharmaceuticals Lim... (TLX)
NasdaqGS: TLX
· Echtzeitkurs · USD
11.88
+0.15 (1.28%)
Zum Schluss: Aug 18, 2026, 8:00 PM
12.20
+2.69%
Vorbörslich: 9:04 AM
Telix Pharmaceuticals Limited (TLX) Stock Price, Analysis & Data
1.28% (1D)
Keine Daten verfügbar
| Geld | 11.78 |
| Marktkapitalisierung | 4.02 Mrd |
| Umsatz (TTM) | 803.79 Mio |
| Nettogewinn (TTM) | -7.13 Mio |
| Beta | 0.60 |
| EPS (ttm) | -0.02 |
| KGV (TTM) | n/a |
| Forward-KGV | 64.47 |
| KBV (TTM) | 9.69 |
| KUV (TTM) | 5.01 |
| Earnings Date | n/a |
| Brief | 10.32 |
| Volumen | 42,691 |
| Ø Vol. (20D) | 158,151 |
| Eröffnung | 11.87 |
| Vortagesschluss | 11.73 |
| Tagesspanne | 11.84 - 11.98 |
| 52-Wk Range | 6.28 - 12.60 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with adv...
Branche Biotechnology
Sektor Healthcare
IPO Datum Nov 14, 2024
Mitarbeiter 1,120
Börse NasdaqGS
Tickersymbol TLX
Website https://telixpharma.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Telix Pharmaceuticals 803.79 Mio, ein Anstieg von 55.61% im Vergleich zum Vorjahr (516.55 Mio). Der Gewinn lag bei -7.13 Mio, ein Rückgang von -121.15 %.
Finanzberichte
Seite 1 von 2